Indian Anti-Diabetes Market to be Worth USD 1,446 Million in 2018, Expects GBI Research

19 Feb 2013 • by Natalie Aster

India is the second diabetes capital of the world after China, with the treatment market growing at a double-digit year-on-year growth rate, presenting both domestic and Multinational Companies (MNCs) with promising opportunities.

India offers lucrative opportunities to both domestic and foreign pharmaceutical players with anti-diabetic product portfolios. In 2011, type 2 diabetes therapeutics dominated the anti-diabetic therapeutics market with an 87% share in value, and accordingly, more than 90% of all R&D pipeline molecules are being studied for the treatment of type 2 diabetes. The type 2 diabetes therapeutics market, although crowded with generics, is being viewed as a significant growth opportunity for newly patent-protected products, owing to high disease prevalence and considerable unmet need.

The R&D product pipeline for diabetes, dominated by Oral Anti-Diabetic (OAD) agents, consists of 194 molecules at various stages of clinical development, the majority being in Phase III trials. The launch of some of these pipeline molecules is anticipated to improve treatment and compliance rates and drive the anti-diabetic market in the forecast period.

Many MNCs are engaged in setting up strategic marketing and distribution agreements with domestic players, in order to improve their patient base and market share in India. Sun Pharma and Merck’s joint venture to bring new anti-diabetics to emerging markets, the USV-Novartis collaboration for the marketing of Galvus, the Lupin-Eli Lilly alliance for the marketing of insulin, and collaborations between Eli Lilly and Boehringer Ingelheim all represent examples of this. MNCs succeed in expanding their patient base, while domestic companies benefit from the pharma giants’ strong sales forces and manufacturing capabilities. Given the impressive growth rate predicted for the diabetes therapeutics market in India, more strategic consolidations are expected to follow during the forecast period.

According to the report “Diabetes Therapeutics Market in India to 2018 - Rapid Uptake of DPP-IV Inhibitors, GLP-1 Agonists and Expanding Insulin Segment to Drive Growth” by GBI Research, the Indian anti-diabetes market was worth at $680.3m in 2011, and is expected to grow at a Compound Annual Growth Rate (CAGR) of 11.3% to reach a value of US$1,446m in 2018, due to the large and growing diabetes population in the country and anticipated launch of many first-in-class and novel molecules during the forecast period.

Report Details:

Diabetes Therapeutics Market in India to 2018 - Rapid Uptake of DPP-IV Inhibitors, GLP-1 Agonists and Expanding Insulin Segment to Drive Growth
Published: January, 2013
Pages: 74
Price: US$ 3,500.00

However, low treatment-seeking and diagnosis rates, poor compliance to medical care, rising healthcare costs and an increasingly competitive market are some of the key hurdles for India’s domestic diabetes market.

More information can be found in the report “Diabetes Therapeutics Market in India to 2018 - Rapid Uptake of DPP-IV Inhibitors, GLP-1 Agonists and Expanding Insulin Segment to Drive Growth” by GBI Research.

To order the report or ask for sample pages contact ps@marketpublishers.com

Contacts

MarketPublishers, Ltd.
Tanya Rezler
Tel: +44 208 144 6009
Fax: +44 207 900 3970
ps@marketpublishers.com
MarketPublishers.com